| Ytd | -57.70% | |
| 1y | -64.42% |
| Open | 2.68 | Prev Close | 2.66 | Low | 2.67 | High | 2.71 | Mkt Cap | 212.85M |
| Vol | 268.12K | Avg Vol | 585.61K | EPS | 0.19 | P/E | 14.16 | Forward P/E | N/A |
| Beta | 2.08 | Short Ratio | 3.35 | Inst. Own | 33.09% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 3.06 | 200-d Avg | 4.24 | 1yr Est | 14.90 |
NAGE News
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Award--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global au
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
As an investigator-led study, MGB is developing the proposed trial in collaboration with the Niagen
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
Niagen Bioscience (NASDAQ:NAGE) held its second-quarter earnings conference call on Tuesday. Below i
Niagen Bioscience, Inc. (NASDAQ: NAGE - Get Free Report) has earned an average recommendation of "Bu
Preclinical study results showcase that CD38, an NAD-consuming enzyme more active with age and infla
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #BioPharma--Niagen Bioscience, Inc. (NASDAQ: NAGE), the globa
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide aden
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE), the glob
[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide aden
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
The launch expands access to Tru Niagen through one of the country’s largest digital retail platform
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript
Niagen Bioscience (NAGE) came out with quarterly earnings of $0.01 per share, in line with the Zacks
Niagen Bioscience (NASDAQ:NAGE) widens FY2026 sales outlook from $138.982 million-$145.299 million t
Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.01 per share which missed the anal
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announc
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global
[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide aden
New epigenetic findings show Niagen NR reduces muscle biological aging and supports healthy muscle f
NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide ri
https://www.sec.gov/Archives/edgar/data/1386570/000121390026077234/ea0297322-424b5_niagen.htm
NB4168, a patented therapeutic candidate designed to have significantly increased bioavailability an
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Niagen Bioscience (NASDAQ:NAGE) with
U.S. stock futures up, Dow futures gain 0.1% as Snap (NYSE: SNAP) shares fall 10.5%, Fastly (NASDAQ:
Niagen Bioscience reaffirms 2026 sales outlook after first-quarter revenue and profit rose alongside
2026 Full Year OutlookNet sales: Increasing between 10-15% year-over-year excluding 2025 net sales a
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleoti
Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleoti
U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting ear
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleot
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleot
Niagen Bioscience estimates the program has generated more than $200 million in third-party research
Shares of Veeva Systems Inc (NYSE: VEEV) gained 11.3% in pre-market trading on upbeat Q4 results and
Niagen Bioscience Inc. surged in after-hours trading after reporting record 2025 results, while main
NAD+ company Niagen Bioscience doubles profits in 2025, eyes acquisitions and new markets as the lon
2026 Outlook
Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.03 per share which beat the analys
Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.05 per share which beat the analys
Divestiture streamlines operations and advances the Company's strategy to fully exit non-core ac